The Punch on MSN8d
Lassa fever death toll hits 53, NCDC traces 191 suspected patients
The death toll from Lassa fever in Nigeria has risen to 53 according to the latest situation report of the disease obtained ...
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...
The Punch Newspapers27d
NCDC confirms 54 Lassa fever cases, 10 deaths
The World Health Organisation has defined Lassa fever as an acute viral haemorrhagic illness caused by the Lassa virus, a member of the arenavirus family of viruses. Humans usually become ...
Morningstar16d
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing next generation immunotherapeutics based on its proprietary arenavirus platform. The company ...
HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...
Hookipa Pharma stock hits 52-week low at $1.71 amid downturn
In a challenging year for biotech firms, Hookipa Pharma Inc (NASDAQ:HOOK). shares have tumbled to a 52-week low, touching down at $1.71. According to InvestingPro analysis, the company, known for its ...
Pharmaceutical Technology25d
Esepapogene zalarnarepvec by Hookipa Pharma for Oropharyngeal Cancer: Likelihood of Approval
Hookipa Pharma (Hookipa) is a clinical-stage biopharmaceutical company that develops novel immunotherapies through its arenavirus platform for cancer and chronic infectious diseases using its ...
Nasdaq16d
HOOKIPA Pharma Completes Enrollment in Phase 1b Clinical Trial of HB-500 for HIV Treatment in Collaboration with Gilead Sciences, Inc.
HOOKIPA Pharma Inc. has announced the completion of participant enrollment in a Phase 1b clinical trial for HB-500, a next-generation therapeutic vaccine aimed at treating HIV. The trial ...
Frontiers12d
Rapid Response Subunit Vaccine Design in the Absence of Structural Information
Prior to 2020, the threat of a novel viral pandemic was omnipresent but largely ignored. Just 12 months prior to the Coronavirus disease 2019 (COVID-19) pandemic our team received funding from the ...